ABUS (Arbutus Biopharma) Cyclically Adjusted Revenue per Share: $0.22 (As of Mar. 2026)


ABUS Arbutus Biopharma Corp ABUS
53 GF Score
Price $4.87
GF Value $51.17
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Cyclically Adjusted Revenue per Share?

Arbutus Biopharma ABUS +3.07% 53 Cyclically Adjusted Revenue per Share is $0.22 as of Mar. 2026. GuruFocus rates ABUS with a GF Score™ of 53/100 and a GF Value™ of $51.17 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Arbutus Biopharma's adjusted revenue per share for the three months ended in Mar. 2026 was $0.918. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.22 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Arbutus Biopharma's average Cyclically Adjusted Revenue Growth Rate was 29.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -29.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -25.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Arbutus Biopharma was -12.50% per year. The lowest was -29.40% per year. And the median was -21.50% per year.

As of today (2026-07-05), Arbutus Biopharma's current stock price is $4.87. Arbutus Biopharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $0.22. Arbutus Biopharma's Cyclically Adjusted PS Ratio of today is 22.14.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arbutus Biopharma was 36.69. The lowest was 1.02. And the median was 5.92.


Arbutus Biopharma  (NAS:ABUS) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Arbutus Biopharma's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=4.87/0.22
=22.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Arbutus Biopharma was 36.69. The lowest was 1.02. And the median was 5.92.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Arbutus Biopharma Cyclically Adjusted Revenue per Share Related Terms


Arbutus Biopharma Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Arbutus Biopharma's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arbutus Biopharma Cyclically Adjusted Revenue per Share Chart

Arbutus Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.45 0.37 0.27 0.19 0.13

Arbutus Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.17 0.16 0.13 0.22

ABUS vs EVMN, ANNX, TBPH: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Arbutus Biopharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arbutus Biopharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Cyclically Adjusted PS Ratio falls into.


ABUS
53GF Score
Arbutus Biopharma Corp ABUS
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Arbutus Biopharma's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.918/330.2130*330.2130
=0.918

Current CPI (Mar. 2026) = 330.2130.

Arbutus Biopharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.006 241.018 0.008
201609 0.014 241.428 0.019
201612 -0.004 241.432 -0.005
201703 0.004 243.801 0.005
201706 0.019 244.955 0.026
201709 0.126 246.819 0.169
201712 0.046 246.524 0.062
201803 0.026 249.554 0.034
201806 0.022 251.989 0.029
201809 0.029 252.439 0.038
201812 0.030 251.233 0.039
201903 0.012 254.202 0.016
201906 0.011 256.143 0.014
201909 0.054 256.759 0.069
201912 0.027 256.974 0.035
202003 0.022 258.115 0.028
202006 0.022 257.797 0.028
202009 0.019 260.280 0.024
202012 0.028 260.474 0.035
202103 0.023 264.877 0.029
202106 0.024 271.696 0.029
202109 0.033 274.310 0.040
202112 0.024 278.802 0.028
202203 0.085 287.504 0.098
202206 0.096 296.311 0.107
202209 0.039 296.808 0.043
202212 0.040 296.797 0.045
202303 0.041 301.836 0.045
202306 0.028 305.109 0.030
202309 0.028 307.789 0.030
202312 0.013 306.746 0.014
202403 0.009 312.332 0.010
202406 0.009 314.175 0.009
202409 0.007 315.301 0.007
202412 0.008 315.605 0.008
202503 0.009 319.799 0.009
202506 0.056 322.561 0.057
202509 0.003 324.800 0.003
202512 0.005 324.054 0.005
202603 0.918 330.213 0.918

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.22 mean?
Arbutus Biopharma (ABUS) has a Cyclically Adjusted Revenue per Share of $0.22 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Cyclically Adjusted Revenue per Share too high?
Arbutus Biopharma's current Cyclically Adjusted Revenue per Share is $0.22. Overall, Arbutus Biopharma has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Cyclically Adjusted Revenue per Share compare to EVMN and ANNX?
Arbutus Biopharma's Cyclically Adjusted Revenue per Share of $0.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Cyclically Adjusted Revenue per Share is $0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.17, compared to a current price of $4.87 — trading 90.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $0.22. Arbutus Biopharma's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Cyclically Adjusted Revenue per Share is $0.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.87 is trading 90.5% below its estimated GF Value™ of $51.17. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Cyclically Adjusted Revenue per Share: $0.22
  • GF Value™: $51.17 vs. price of $4.87 (90.5% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
53GF Score

Get the complete analysis for ABUS

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.87
Price
$51.17
GF Value